Adrenocortical cancer: late diagnosis of the disease on the example of a clinical case. Case report
- 作者: Starostina E.1, Molashenko N.1, Levshina A.2, Pachuashvili N.1,2, Chevais A.1, Isaeva M.1, Getazheev K.3, Beltsevich D.1, Platonova N.1, Troshina E.1
-
隶属关系:
- Endocrinology Research Centre
- Sechenov First Moscow State Medical University (Sechenov University)
- Pirogov Russian National Research Medical University
- 期: 卷 95, 编号 12 (2023)
- 页面: 1179-1184
- 栏目: Clinical notes
- URL: https://journals.rcsi.science/0040-3660/article/view/258746
- DOI: https://doi.org/10.26442/00403660.2023.12.202430
- ID: 258746
如何引用文章
全文:
详细
Adrenocortical carcinoma (ACC) is a rare malignant tumor originating in the adrenal cortex and characterized by poor 5-year survival. It occurs with a frequency of 2–4 cases per 2 million in the population. Women are more frequently affected than men and it is mostly detected in the fourth and fifth decades. In the most of cases, the cancerogenesis occurs sporadically because of gene driver mutations in somatic adrenocortical cells, in other cases it can be found as part of a genetically determined syndrome such as Li–Fraumeni syndrome or Wermer's syndrome (multiple endocrine adenomatosis type I). ACC most frequently happens occurs without symptoms in the initial stages leading to poor diagnoses. Because of this lack of early detection, the tumor is not considered malignant reducing the benefits of further treatment. Sometimes the fact that the resected tumor is indeed adrenocortical carcinoma becomes clear only after recurrence, or after the appearance of metastases. We present a case of adrenocortical carcinoma in a 46-year-old woman who went to the doctor in 1.5 year after symptoms were manfested. This clinical case illustrates the consequences of late diagnosis of a malignant tumor. We would like to emphasize the importance of timely detection of a neoplasm, using all of the potential of laboratory-instrumental and genomic analysis. Due to low oncological awareness, our patient was slow to seek medical help, which in turn led not only to metastases, but also to complications in the cardiovascular system.
作者简介
Evgenia Starostina
Endocrinology Research Centre
编辑信件的主要联系方式.
Email: colpakova.ev@mail.ru
ORCID iD: 0000-0003-2283-8958
врач-эндокринолог, сотр. Координационного совета ФГБУ «НМИЦ эндокринологии»
俄罗斯联邦, MoscowNatalya Molashenko
Endocrinology Research Centre
Email: colpakova.ev@mail.ru
ORCID iD: 0000-0001-6265-1210
канд. мед. наук, вед. науч. сотр.
俄罗斯联邦, MoscowAnna Levshina
Sechenov First Moscow State Medical University (Sechenov University)
Email: colpakova.ev@mail.ru
ORCID iD: 0000-0002-9315-3801
студентка
俄罗斯联邦, MoscowNano Pachuashvili
Endocrinology Research Centre; Sechenov First Moscow State Medical University (Sechenov University)
Email: colpakova.ev@mail.ru
ORCID iD: 0000-0002-8136-0117
мл. науч. сотр. лаб. эндокринной биофотоники ФГБУ «НМИЦ эндокринологии»; ординатор Института клинической морфологии и цифровой патологии ФГАОУ ВО «Первый МГМУ им. И. М. Сеченова» (Сеченовский Университет)
俄罗斯联邦, Moscow; MoscowAnastassia Chevais
Endocrinology Research Centre
Email: colpakova.ev@mail.ru
ORCID iD: 0000-0001-5592-4794
аспирант
俄罗斯联邦, MoscowMariya Isaeva
Endocrinology Research Centre
Email: colpakova.ev@mail.ru
ORCID iD: 0000-0002-9963-6783
аспирант
俄罗斯联邦, MoscowKantemir Getazheev
Pirogov Russian National Research Medical University
Email: colpakova.ev@mail.ru
ORCID iD: 0000-0001-5193-0556
клин. ординатор
俄罗斯联邦, MoscowDmitry Beltsevich
Endocrinology Research Centre
Email: colpakova.ev@mail.ru
ORCID iD: 0000-0001-7098-4584
д-р мед. наук, проф., гл. науч. сотр. отд. хирургии
俄罗斯联邦, MoscowNadezhda Platonova
Endocrinology Research Centre
Email: colpakova.ev@mail.ru
ORCID iD: 0000-0001-6388-1544
д-р мед. наук, проф., зав. отд. терапевтической эндокринологии
俄罗斯联邦, MoscowEkaterina Troshina
Endocrinology Research Centre
Email: colpakova.ev@mail.ru
ORCID iD: 0000-0002-8520-8702
чл.-кор. РАН, д-р мед. наук, проф., зам. дир. – дир. Института клинической эндокринологии
俄罗斯联邦, Moscow参考
- Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12(3):667-80. doi: 10.1677/erc.1.01029
- Kerkhofs TMA, Verhoeven RHA, Van der Zwan JM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579-86. doi: 10.1016/j.ejca.2013.02.034
- Fassnacht M, Kroiss M, Allolio B. Update in Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2013;98(12):4551-64. doi: 10.1210/jc.2013-3020
- Lloyd RV, Osamura RY, Klöppel G, Rosai JE. WHO Classification of Tumours of Endocrine Organs. 4th ed., 2017.
- Sidhu S, Marsh DJ, Theodosopoulos G, et al. Comparative Genomic Hybridization Analysis of Adrenocortical Tumors. J Clin Endocrinol Metab. 2002;87(7):3467-74. doi: 10.1210/jcem.87.7.8697
- Barreau O, de Reynies A, Wilmot-Roussel H, et al. Clinical and Pathophysiological Implications of Chromosomal Alterations in Adrenocortical Tumors: An Integrated Genomic Approach. J Clin Endocrinol Metab. 2012;97(2):E301-11. doi: 10.1210/jc.2011-1588
- Assié G, Letouzé E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46(6):607-12. doi: 10.1038/ng.2953
- Juhlin CC, Goh G, Healy JM, et al. Whole-Exome Sequencing Characterizes the Landscape of Somatic Mutations and Copy Number Alterations in Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2015;100(3):E493-502. doi: 10.1210/jc.2014-3282
- Reincke M, Karl M, Travis WH, et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab. 1994;78(3):790-4. doi: 10.1210/jcem.78.3.8126158
- Libè R, Groussin L, Tissier F, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res. 2007;13(3):844-50. doi: 10.1158/1078-0432.CCR-06-2085
- Wasserman JD, Zambetti GP, Malkin D. Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol. 2012;351(1):101-10. doi: 10.1016/j.mce.2011.09.010
- Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States. Cancer. 2008;113(11):3130-6. doi: 10.1002/cncr.23886
- Мельниченко Г.А., Стилиди И.С., Алексеев Б.Я., и др. Федеральные клинические рекомендации по диагностике и лечению адренокортикального рака. Проблемы эндокринологии. 2014;60(2):51-67 [Melnichenko GA, Stilidi IS, Alekseev BYa, et al. Federal clinical practice guidelines on the diagnostics and treatment of adrenocortical cancer. Problems of Endocrinology. 2014;60(2):51-67 (in Russian)].
- Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2009;23(2):273-89. doi: 10.1016/j.beem.2008.10.008
- Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91(6):2027-37. doi: 10.1210/jc.2005-2639
- Pacak K. Preoperative Management of the Pheochromocytoma Patient. J Clin Endocrinol Metab. 2007;92(11):4069-79. doi: 10.1210/jc.2007-1720
- Kinney MAO, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth. 2002;16(3):359-69. doi: 10.1053/jcan.2002.124150
- Nieman LK. Approach to the Patient with an Adrenal Incidentaloma. J Clin Endocrinol Metab. 2010;95(9):4106-13. doi: 10.1210/jc.2010-0457
- Sturgeon C, Shen WT, Clark OH, et al. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg. 2006;202(3):423-30. doi: 10.1016/j.jamcollsurg.2005.11.005
- Petersenn S, Richter PA, Broemel T, et al. Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. Eur J Endocrinol. 2015;172(4):415-22. doi: 10.1530/EJE-14-0916
- Angeli A, Osella G, Ali A, Terzolo M. Adrenal Incidentaloma: An Overview of Clinical and Epidemiological Data from the National Italian Study Group. Hormones. 1997;47(4-6):279-83. doi: 10.1159/000185477
- Metser U, Miller E, Lerman H, et al. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med. 2006;47(1):32-7.
- Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91(7):2665-71. doi: 10.1210/jc.2005-2612
- Leboulleux S, Dromain C, Bonniaud G, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab. 2006;91(3):920-5. doi: 10.1210/jc.2005-1540
- Creemers SG, Hofland LJ, Korpershoek E, et al. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma. Endocr Relat Cancer. 2016;23(1):R43-69. doi: 10.1530/ERC-15-0452
- Livhits M, Li N, Yeh MW, Harari A. Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease. Surgery. 2014;156(6):1531. doi: 10.1016/j.surg.2014.08.047
- Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005;6(4):386-94.
- Puglisi S, Calabrese A, Basile V, et al. New perspectives for mitotane treatment of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2020;34(3):101415. doi: 10.1016/j.beem.2020.101415
- Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997;122(6):1212-8. doi: 10.1016/s0039-6060(97)90229-4
- Allolio B, Fassnacht M. Adrenocortical Carcinoma: Clinical Update. J Clin Endocrinol Metab. 2006;91(6):2027-37. doi: 10.1210/jc.2005-2639
- Grubbs EG, Callender GG, Xing Y, et al. Recurrence of Adrenal Cortical Carcinoma Following Resection: Surgery Alone Can Achieve Results Equal to Surgery Plus Mitotane. Ann Surg Oncol. 2010;17(1):263-70. doi: 10.1245/s10434-009-0716-x
- Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. Cancer. 2009;115(2):243-50. doi: 10.1002/cncr.24030
- Libé R, Borget I, Ronchi CL, et al. Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol. 2015;26(10):2119-25. doi: 10.1093/annonc/mdv329
- Margonis G, Kim Y, Tran T, et al. Outcomes Following Resection of Cortisol-secreting Adrenocortical Carcinoma. Am J Surg. 2015;211. doi: 10.1016/j.amjsurg.2015.09.020
- Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes. 2008;15(3):221-6. doi: 10.1097/MED.0b013e3282fdf4c0
- Terzolo M, Baudin AE, Ardito A, et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol. 2013;169(3):263-70. doi: 10.1530/EJE-13-0242
- Nader N, Raverot G, Emptoz-Bonneton A, et al. Mitotane Has an Estrogenic Effect on Sex Hormone-Binding Globulin and Corticosteroid-Binding Globulin in Humans. J Clin Endocrinol Metab. 2006;91(6):2165-70. doi: 10.1210/jc.2005-2157
- Kroiss M, Quinkler M, Lutz WK, et al. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2011;75(5):585-91. doi: 10.1111/j.1365-2265.2011.04214.x
- Berruti A, Grisanti S, Pulzer A, et al. Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2017;102(4):1358-65. doi: 10.1210/jc.2016-2894
- Fassnacht M, Terzolo M, Allolio B, et al. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. N Engl J Med. 2012;366(23):2189-97. doi: 10.1056/NEJMoa1200966